Siponimod
Brand Names: Mayzent
Methodology & AI Transparency ⓘ
Siponimod Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 2 mg/1 Tablet, Film Coated and .25 mg/1 Tablet, Film Coated and manufactured/labeled by Novartis Pharma Stein AG (NDC 17088-0191, 0078-0986), Siponimod operates within systemic sphingosine 1-phosphate receptor modulator treatment algorithms requiring prescription authorization.
- 2 Real-world patient consensus: Real-world cohort score of 82% across 10 de-identified Siponimod entries.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $148.23 cash mean against $363.16 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Siponimod): nausea (8.2%), headache (8%), dizziness (5.5%).
Ask our AI Specialists anything about Siponimod
Siponimod Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 2 mg/1 Tablet, Film Coated and .25 mg/1 Tablet, Film Coated and manufactured/labeled by Novartis Pharma Stein AG (NDC 17088-0191, 0078-0986), Siponimod operates within systemic sphingosine 1-phosphate receptor modulator treatment algorithms requiring prescription authorization.
Delivered via 2 mg/1 Tablet, Film Coated and .25 mg/1 Tablet, Film Coated (systemic; NDC 17088-0191, 0078-0986), Siponimod mediates sphingosine 1-phosphate receptor modulator physiological effects manufactured/labeled by Novartis Pharma Stein AG with dose-dependent receptor occupancy and systemic clearance.
Following administration (2 mg/1 Tablet, Film Coated), Siponimod achieves Consistent 67%–79% gastrointestinal absorption profile for Siponimod bioavailability and cmax attained 2–5 hours post-administration of siponimod onset, governed by a Elimination kinetics span 8 to 19 hours per Siponimod clinical pharmacology terminal half-life through systemic clearance of siponimod integrates hepatic phase ii conjugation with renal filtration.
Before initiating Siponimod at 2 mg/1 Tablet, Film Coated, clinical safety checklists rule out previous anaphylactoid or exfoliative reaction attributed to siponimod; clinical scenarios where sphingosine 1-phosphate receptor modulator exposure from siponimod poses unacceptable risk. Logged tolerability patterns center on nausea (8.2% of reports), headache (8% of reports), dizziness (5.5% of reports).
Verify medication reconciliation lists so Siponimod is not inadvertently duplicated with another sphingosine 1-phosphate receptor modulator.
Unstandardized herbal extracts may interact pharmacodynamically with Siponimod maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Siponimod
- Clinical scenarios where sphingosine 1-phosphate receptor modulator exposure from Siponimod poses unacceptable risk
Logged Side-Effect Incidence (10 Reports)
Siponimod Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Siponimod)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Siponimod: Disentangling disability and relapses in secondary progressive By controlling the confounding impact of on-study relapses on confirmed disability progression, these statistical approaches provide a methodological framework to assess treatment effects on disability progression in relapsing... Multiple sclerosis (Houndmills, Basingstoke, England) • 2021-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33205682 ↗ |
Siponimod Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.4500/unit (~$103.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $363.16 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $148.23 / mo | View logs ↓ |
Siponimod Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Siponimod RxNorm Concept ID | RXN-170880191-2834 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.4500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $363.16 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $148.23 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 82.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Siponimod Patient Community, Cohort Filters & Dosage Logs
Deterministic Siponimod reference combining NIH RxNorm (RXN-170880191-2834), Medicaid NADAC ($3.4500/unit), and anonymous cohort outcomes (82% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Siponimod community threads and patient logs by age, biological sex, dosage, and treatment duration.